JPMorgan Chase & Co. Lowers Stake in Harrow, Inc. (NASDAQ:HROW)

JPMorgan Chase & Co. decreased its position in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 80.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 46,877 shares of the company's stock after selling 191,490 shares during the period. JPMorgan Chase & Co. owned 0.13% of Harrow worth $1,573,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in HROW. Barclays PLC boosted its holdings in Harrow by 301.9% in the 3rd quarter. Barclays PLC now owns 52,593 shares of the company's stock worth $2,365,000 after buying an additional 39,506 shares during the period. Brookstone Capital Management bought a new position in shares of Harrow in the fourth quarter worth about $275,000. SG Americas Securities LLC grew its position in shares of Harrow by 158.5% during the fourth quarter. SG Americas Securities LLC now owns 30,689 shares of the company's stock worth $1,030,000 after purchasing an additional 18,815 shares in the last quarter. Sonora Investment Management Group LLC purchased a new stake in shares of Harrow during the fourth quarter worth about $518,000. Finally, Bank of New York Mellon Corp raised its stake in Harrow by 8.4% during the 4th quarter. Bank of New York Mellon Corp now owns 86,447 shares of the company's stock valued at $2,900,000 after purchasing an additional 6,690 shares during the period. Hedge funds and other institutional investors own 72.76% of the company's stock.

Harrow Trading Up 0.4 %

Shares of Harrow stock traded up $0.10 during trading on Thursday, hitting $24.87. The stock had a trading volume of 16,348 shares, compared to its average volume of 501,347. The stock has a market cap of $886.71 million, a PE ratio of -26.58 and a beta of 0.46. Harrow, Inc. has a 12 month low of $10.04 and a 12 month high of $59.23. The firm's fifty day simple moving average is $25.16 and its 200-day simple moving average is $34.29. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44.

Harrow (NASDAQ:HROW - Get Free Report) last released its earnings results on Thursday, March 27th. The company reported $0.25 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.14. The firm had revenue of $66.83 million for the quarter, compared to analysts' expectations of $66.01 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. As a group, sell-side analysts expect that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. HC Wainwright reiterated a "buy" rating and set a $57.00 price objective on shares of Harrow in a research report on Monday, March 31st. B. Riley cut their target price on shares of Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a report on Tuesday, April 1st.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.